Profile data is unavailable for this security.
About the company
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
- Revenue in USD (TTM)1.73bn
- Net income in USD682.64m
- Incorporated1998
- Employees991.00
- LocationPTC Therapeutics Inc500 Warren Corporate Center DriveWARREN 07059United StatesUSA
- Phone+1 (302) 636-5400
- Fax+1 (302) 636-5454
- Websitehttps://www.ptcbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics Inc | 376.07m | -16.14m | 3.07bn | 354.00 | -- | 16.12 | -- | 8.17 | -0.1325 | -0.1325 | 2.93 | 1.54 | 0.962 | 1.97 | 3.43 | 1,062,350.00 | -4.13 | -48.93 | -5.65 | -57.14 | 90.24 | -- | -4.29 | -147.21 | 2.99 | -3.84 | 0.3651 | -- | 91.34 | -- | 88.47 | -- | 101.59 | -- |
| Supernus Pharmaceuticals Inc | 718.95m | -38.55m | 3.17bn | 674.00 | -- | 2.98 | 59.59 | 4.40 | -0.6839 | -0.6839 | 12.70 | 18.48 | 0.5098 | 1.09 | 4.36 | -- | -2.73 | 2.01 | -3.52 | 2.67 | 89.63 | 87.96 | -5.36 | 4.66 | 1.66 | -- | -- | -- | 8.63 | 6.68 | -152.19 | -- | -- | -- |
| Prestige Consumer Healthcare Inc | 1.10bn | 186.50m | 3.24bn | 600.00 | 18.12 | 1.77 | 14.97 | 2.94 | 3.78 | 3.78 | 22.38 | 38.66 | 0.3234 | 3.07 | 6.17 | 1,839,343.00 | 5.47 | 4.13 | 5.67 | 4.30 | 56.12 | 56.31 | 16.90 | 13.13 | 1.93 | 8.28 | 0.3657 | 0.00 | 1.10 | 3.39 | 2.52 | 8.57 | -13.84 | -- |
| Tarsus Pharmaceuticals Inc | 451.36m | -66.42m | 3.30bn | 370.00 | -- | 9.59 | -- | 7.30 | -1.61 | -1.61 | 10.81 | 8.07 | 0.9612 | 8.78 | 6.85 | 1,219,892.00 | -14.14 | -27.80 | -18.38 | -32.78 | 93.20 | 93.45 | -14.72 | -53.60 | 3.82 | -- | 0.1742 | -- | 146.71 | -- | 42.52 | -- | 84.92 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 677.56m | 59.01m | 3.52bn | 366.00 | 61.76 | 6.18 | 58.14 | 5.20 | 0.7448 | 0.7448 | 8.58 | 7.44 | 1.01 | 1.91 | 23.64 | 1,851,268.00 | 8.78 | 2.35 | 10.69 | 2.75 | 88.54 | 87.48 | 8.71 | 3.40 | 3.39 | -- | 0.00 | 0.00 | 60.09 | -- | 236.61 | -- | 40.84 | -- |
| Corcept Therapeutics Inc | 761.41m | 99.65m | 3.83bn | 730.00 | 43.32 | 5.88 | 37.96 | 5.03 | 0.8303 | 0.8303 | 6.35 | 6.11 | 0.908 | 1.03 | 13.39 | 1,043,023.00 | 11.88 | 17.68 | 14.54 | 20.76 | 98.30 | 98.47 | 13.09 | 20.88 | 2.85 | -- | 0.00 | 0.00 | 12.79 | 16.56 | -29.43 | -1.23 | -29.80 | -- |
| ADMA Biologics Inc | 510.17m | 146.93m | 3.95bn | 647.00 | 27.65 | 8.26 | 25.47 | 7.74 | 0.5996 | 0.5996 | 2.08 | 2.01 | 0.9168 | 1.15 | 4.90 | 788,520.90 | 26.40 | 9.62 | 29.75 | 10.91 | 57.39 | 44.75 | 28.80 | 12.51 | 3.74 | 37.09 | 0.1313 | 0.00 | 19.63 | 64.60 | -25.67 | -- | 12.46 | -- |
| Indivior Pharmaceuticals, Inc | 1.18bn | 122.00m | 4.00bn | 1.03k | 33.34 | -- | 27.02 | 3.39 | 0.9592 | 0.9592 | 9.20 | -1.66 | 0.8194 | 1.03 | 4.63 | 1,145,631.00 | 8.68 | -1.36 | 26.23 | -2.98 | 85.51 | 84.87 | 10.59 | -2.47 | 0.7938 | 9.33 | 2.80 | -- | 8.69 | 8.64 | 101.55 | -56.87 | 34.66 | -- |
| Ligand Pharmaceuticals Inc | 251.23m | 48.58m | 4.04bn | 68.00 | 97.48 | 4.19 | 48.79 | 16.08 | 2.08 | 2.08 | 12.77 | 48.34 | 0.2066 | 1.01 | 5.47 | 3,694,603.00 | 4.00 | 1.82 | 4.09 | 1.92 | 94.27 | 82.57 | 19.34 | 10.30 | 24.30 | -- | 0.3192 | 0.00 | 27.28 | 6.80 | -107.49 | -- | -6.53 | -- |
| Amneal Pharmaceuticals Inc | 2.93bn | 5.90m | 4.33bn | 8.10k | 833.54 | -- | 14.53 | 1.48 | 0.0165 | 0.0165 | 9.17 | -0.3483 | 0.8313 | 3.07 | 3.59 | 362,340.60 | 1.63 | -2.12 | 2.32 | -2.68 | 36.76 | 35.94 | 1.96 | -3.47 | 1.42 | 1.47 | 1.02 | -- | 16.73 | 11.43 | -39.16 | -- | -5.10 | -- |
| TG Therapeutics Inc | 616.29m | 447.18m | 4.69bn | 399.00 | 10.59 | 7.05 | 10.50 | 7.62 | 2.78 | 2.78 | 3.82 | 4.17 | 0.7511 | 0.8534 | 2.83 | 1,544,579.00 | 54.50 | -3.81 | 64.04 | -4.57 | 83.66 | 87.01 | 72.56 | -7.46 | 3.29 | 4.61 | 0.2749 | -- | 87.32 | 426.73 | 1,812.41 | -- | -9.73 | -- |
| Mirum Pharmaceuticals Inc | 521.31m | -23.36m | 5.44bn | 369.00 | -- | 14.86 | 6,170.46 | 10.43 | -0.4783 | -0.4783 | 10.07 | 6.06 | 0.6889 | 4.24 | 5.17 | 1,412,770.00 | -3.09 | -19.72 | -3.96 | -23.84 | 80.77 | 78.68 | -4.48 | -43.34 | 2.55 | -13.32 | 0.4961 | -- | 54.74 | -- | 73.43 | -- | 33.50 | -- |
| PTC Therapeutics, Inc. | 1.73bn | 682.64m | 5.49bn | 991.00 | 8.54 | -- | 7.61 | 3.17 | 7.77 | 7.77 | 20.73 | -2.52 | 0.7518 | 0.9143 | 10.18 | 1,746,372.00 | 29.66 | -14.19 | 44.70 | -19.65 | 97.28 | 94.76 | 39.44 | -29.50 | 2.27 | 5.24 | 1.09 | -- | 114.51 | 35.37 | 287.90 | -- | -13.07 | -- |
| Rhythm Pharmaceuticals Inc | 189.76m | -201.92m | 6.48bn | 414.00 | -- | 45.88 | -- | 34.16 | -3.11 | -3.11 | 2.92 | 4.02 | 0.435 | 0.8762 | 8.51 | 458,350.30 | -45.05 | -50.41 | -60.38 | -61.35 | 89.73 | 89.41 | -103.57 | -210.46 | 4.16 | -36.30 | 0.286 | -- | 45.83 | -- | 23.68 | -- | 34.81 | -- |
| Krystal Biotech Inc | 389.13m | 204.83m | 7.57bn | 295.00 | 37.83 | 6.20 | 35.93 | 19.44 | 6.84 | 6.84 | 13.00 | 41.78 | 0.3257 | 0.6882 | 3.35 | 1,319,085.00 | 17.14 | 2.46 | 18.75 | 2.63 | 94.08 | -- | 52.64 | 13.06 | 9.56 | -- | 0.00 | 0.00 | 33.94 | -- | 129.74 | -- | -4.24 | -- |
Data as of Mar 03 2026. Currency figures normalised to PTC Therapeutics Inc's reporting currency: US Dollar USD
62.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 11.38m | 14.17% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 8.15m | 10.15% |
| RTW Investments LPas of 31 Dec 2025 | 7.75m | 9.65% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 4.75m | 5.92% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 4.21m | 5.24% |
| TD Asset Management, Inc.as of 31 Dec 2025 | 4.14m | 5.15% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 3.63m | 4.52% |
| Armistice Capital LLCas of 31 Dec 2025 | 2.80m | 3.49% |
| Geode Capital Management LLCas of 31 Dec 2025 | 2.02m | 2.51% |
| D. E. Shaw & Co. LPas of 31 Dec 2025 | 1.74m | 2.17% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
